At the annual general meeting of Sedana Medical AB (publ) (SEDANA: FN Stockholm) held May 10, 2021, it was resolved, in accordance with the board of directors' proposal, on a division of shares (split), whereby each current share is divided into four new shares of the same share class (split 4:1). The board of directors were authorized to determine the record date (Sw. avstämningsdag) for the share split.
The board of directors have now resolved that the record date for the share split shall be Thursday, May 27, 2021. Consequently, the last day for trading in the share prior to the split is Tuesday, May 25, 2021, and the first day for trading in the divided shares is Wednesday, May 26, 2021.
The share split will be automatically effectuated through the agency of Euroclear Sweden AB and shareholders do not need to take any specific measures.
In connection to the share split, the ISIN code for the company's shares will be changed. The new ISIN code is: SE0015988373.
After the effectuation of the share split, the total number of shares in the company will amount to 92,186,960.
For additional information, please contact:
Christer Ahlberg, President and CEO, +46 70 675 33 30
Susanne Andersson, CFO, +46 73 066 89 04
Sedana Medical is listed on Nasdaq First North Growth Market in Stockholm.
The company's Certified Adviser is Erik Penser Bank, +46 8 463 83 00,
About Sedana Medical
Sedana Medical AB (publ) develops and sells the medical device AnaConDa for the administration of volatile anaesthetics. Through a combination of AnaConDa and the drug candidate Sedaconda (isoflurane), Sedana Medical provides inhaled sedation for mechanically ventilated intensive care patients. The company has applied for marketing approval in Europe for Sedaconda and expects an approval in the second half of 2021.
Today, mechanically ventilated intensive care patients are sedated intravenously which leads to several challenges for both patients and care givers. Challenges that are solved by inhaled sedation. Globally, seven to eight million patients are estimated to be sedated in intensive care due to mechanical ventilation, evenly distributed between the US, Europe, and Asia. These patients are on average sedated three to four days. Sedana Medical estimates the total market potential to SEK 20-30 billion. Three years after marketing approval in Europe, Sedana Medical expects sales of SEK 500 million in Europe and an EBITDA margin of about 40 percent. The company has initiated processes to obtain marketing approval in the US in 2024 and in markets outside the EU.
Sedana Medical has direct sales in Benelux, France, Germany, Great Britain, the Nordics and Spain as well as external distributors in other parts of Europe, Australia, Canada, China, India, Israel, Japan, Mexico and South Korea. The company was founded in 2005 and is headquartered in Stockholm, Sweden, with medical device development in Ireland.